Genetics

This blog post examines a recent case–control study investigating the role of angiotensin-converting enzyme 2 (ACE2) in multiple sclerosis (MS). It discusses how elevated serum ACE2 levels in patients with MS, together with significant associations between ACE2 gene polymorphisms and disease susceptibility, support the idea that ACE2 may represent both a clinically relevant biomarker and a genetic contributor to MS pathogenesis. The post also considers the biological significance of these findings within the renin–angiotensin system, highlights the study’s methodological strengths and limitations, and explores how this research may inform future biomarker development and precision medicine approaches in neuroimmunology.